Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Oct 31, 2025 | (Q2)Jul 31, 2025 | (Q1)Apr 30, 2025 | (FY)Jan 31, 2025 | (Q4)Jan 31, 2025 | (Q3)Oct 31, 2024 | (Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -7.07%1.72B | -36.32%1.36B | -44.44%1.23B | -34.70%7.61B | -48.33%1.4B | -34.13%1.85B | -31.19%2.14B | -26.64%2.21B | 84.16%11.65B | 37.72%2.7B |
| Cost of revenue | -43.96%654M | -53.54%584M | -56.76%598M | -43.63%4.88B | -39.90%1.07B | -45.03%1.17B | -46.60%1.26B | -42.25%1.38B | 92.55%8.66B | 21.48%1.79B |
| Gross profit | 55.69%1.07B | -11.86%780M | -23.95%632M | -8.80%2.72B | -64.81%322M | -0.58%686M | 16.60%885M | 33.39%831M | 63.49%2.99B | 86.35%915M |
| Operating expense | 39.51%113M | 5.22%121M | 56.04%142M | 57.47%622M | 260.34%209M | -17.35%81M | -0.86%115M | -25.41%91M | 17.56%395M | -48.67%58M |
| Staff costs | ---- | ---- | ---- | 57.07%311M | ---- | ---- | ---- | ---- | 41.43%198M | ---- |
| Selling and administrative expenses | 24.67%187M | 7.47%187M | 90.65%204M | 26.40%158M | 186.90%241M | -2.60%150M | 24.29%174M | -23.02%107M | -11.35%125M | 159.15%84M |
| -General and administrative expense | 24.67%187M | 7.47%187M | 90.65%204M | 26.40%158M | 186.90%241M | -2.60%150M | 24.29%174M | -23.02%107M | -11.35%125M | 159.15%84M |
| Depreciation and amortization | ---- | ---- | ---- | 11.32%59M | ---- | ---- | ---- | ---- | 51.43%53M | ---- |
| -Depreciation | ---- | ---- | ---- | 13.04%52M | ---- | ---- | ---- | ---- | 53.33%46M | ---- |
| -Amortization | ---- | ---- | ---- | 0.00%7M | ---- | ---- | ---- | ---- | 40.00%7M | ---- |
| Rent and land expenses | ---- | ---- | ---- | -33.33%2M | ---- | ---- | ---- | ---- | 200.00%3M | ---- |
| Other operating expenses | ---- | ---- | ---- | 480.95%122M | ---- | ---- | ---- | ---- | -8.70%21M | ---- |
| Total other operating income | 7.25%74M | 11.86%66M | 287.50%62M | 500.00%30M | 23.08%32M | 23.21%69M | 145.83%59M | -5.88%16M | 25.00%5M | 146.43%26M |
| Operating profit | 57.85%955M | -14.42%659M | -33.78%490M | -18.90%2.1B | -86.81%113M | 2.20%605M | 19.75%770M | 47.70%740M | 73.84%2.59B | 126.72%857M |
| Net non-operating interest income (expenses) | 12.42%-388M | -20.45%-536M | 5.91%-350M | -74.79%-1.89B | -50.63%-476M | -81.56%-443M | -120.30%-445M | -85.07%-372M | -97.98%-1.08B | -125.71%-316M |
| Non-operating interest income | ---- | ---- | ---- | 48.44%95M | ---- | ---- | ---- | ---- | 52.38%64M | ---- |
| Non-operating interest expense | -12.42%388M | 20.45%536M | -5.91%350M | 72.60%1.96B | 50.63%476M | 81.56%443M | 120.30%445M | 85.07%372M | 95.02%1.14B | 78.53%316M |
| Total other finance cost | ---- | ---- | ---- | 175.00%22M | ---- | ---- | ---- | ---- | 60.00%8M | ---- |
| Net investment income | -231.43%-46M | 35M | ||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | 55.86%226M | 2,316.67%145M | ||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | -175.00%-9M | 340.00%12M | ||||||||
| Income from associates and other participating interests | 1,200.00%52M | 1,300.00%56M | 6,300.00%64M | 133.33%21M | 12M | -20.00%4M | -50.00%4M | 125.00%1M | 156.25%9M | 0 |
| Special income (charges) | 3,380.00%820M | 72.83%-25M | ||||||||
| Less:Impairment of capital assets | ---- | ---- | ---- | -136.00%-9M | ---- | ---- | ---- | ---- | -78.81%25M | ---- |
| Less:Other special charges | ---- | ---- | ---- | -13,000.00%-786M | ---- | ---- | ---- | ---- | 82.86%-6M | ---- |
| Less:Write off | ---- | ---- | ---- | -516.67%-25M | ---- | ---- | ---- | ---- | -33.33%6M | ---- |
| Other non-operating income (expenses) | -304.58%-268M | -575.00%-19M | 25.00%-9M | -1,900.00%-108M | 764.29%484M | 131M | 4M | -12M | -62.50%6M | 56M |
| Income before tax | 18.18%351M | -51.95%160M | -45.38%195M | -33.92%1.12B | -77.72%133M | -15.86%297M | -25.84%333M | 20.61%357M | 98.25%1.7B | 273.13%597M |
| Income tax | 100.00%106M | -47.14%37M | -43.52%61M | -184.09%-465M | -131.68%-64M | -29.33%53M | -59.77%70M | 5.88%108M | 107.12%553M | 296.08%202M |
| Net income | 0.41%245M | -53.23%123M | -46.18%134M | 38.79%1.59B | -50.13%197M | -12.23%244M | -4.36%263M | 28.35%249M | 94.22%1.14B | 262.39%395M |
| Net income continuous operations | 0.41%245M | -53.23%123M | -46.18%134M | 38.79%1.59B | -50.13%197M | -12.23%244M | -4.36%263M | 28.35%249M | 94.22%1.14B | 262.39%395M |
| Noncontrolling interests | -86.36%6M | -63.33%22M | -58.70%19M | 88.76%336M | -56.41%51M | 46.67%44M | 33.33%60M | 428.57%46M | 17,900.00%178M | 288.71%117M |
| Net income attributable to the company | 19.50%239M | -50.25%101M | -43.35%115M | 29.56%1.25B | -47.48%146M | -19.35%200M | -11.74%203M | -2.40%203M | 63.67%964M | 62.57%278M |
| Preferred stock dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Other under preferred stock dividend | 518.75%99M | 0.00%35M | -8.11%34M | 0 | 2.94%35M | -54.29%16M | 0.00%35M | 15.63%37M | 0 | 133.01%34M |
| Net income attributable to common stockholders | -23.91%140M | -60.71%66M | -51.20%81M | 29.56%1.25B | -54.51%111M | -13.62%184M | -13.85%168M | -5.68%166M | 63.67%964M | -10.95%244M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -22.58%0.048 | -58.93%0.023 | -48.21%0.029 | 30.88%0.373 | -54.76%0.038 | -15.07%0.062 | -16.42%0.056 | -8.20%0.056 | 70.66%0.285 | 104.88%0.084 |
| Diluted earnings per share | -63.93%0.022 | -58.18%0.023 | -48.21%0.029 | 31.32%0.369 | -55.42%0.037 | -15.28%0.061 | -16.67%0.055 | -6.67%0.056 | 68.26%0.281 | 102.44%0.083 |
| Dividend per share | 100.00%0.02 | 0.00%0.01 | 0.01 | 0.00%0.03 | -50.00%0.01 | 0.01 | 0.00%0.01 | 0 | 0.00%0.03 | 100.00%0.02 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.